Production (Stage)
AstraZeneca PLC
AZNCF
$143.25
$2.131.51%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.92B | 1.50B | 1.43B | 1.93B | 2.18B |
| Total Depreciation and Amortization | 1.28B | 1.16B | 1.32B | 1.25B | 1.26B |
| Total Amortization of Deferred Charges | -- | 200.00M | -- | -- | -- |
| Total Other Non-Cash Items | -61.00M | 402.00M | 595.00M | 34.00M | -493.00M |
| Change in Net Operating Assets | -426.00M | -350.00M | 41.00M | -129.00M | -455.00M |
| Cash from Operations | 3.71B | 2.91B | 3.38B | 3.09B | 2.49B |
| Capital Expenditure | -429.00M | -708.00M | -417.00M | -382.00M | -417.00M |
| Sale of Property, Plant, and Equipment | 1.00M | 2.00M | 0.00 | 0.00 | 53.00M |
| Cash Acquisitions | -362.00M | -274.00M | -263.00M | -2.30B | -948.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -463.00M | -201.00M | -834.00M | -193.00M | -1.10B |
| Cash from Investing | -1.25B | -1.18B | -1.51B | -2.87B | -2.41B |
| Total Debt Issued | 1.10B | -572.00M | -415.00M | 1.50B | 5.98B |
| Total Debt Repaid | -85.00M | -119.00M | -2.09B | -2.71B | -81.00M |
| Issuance of Common Stock | 8.00M | 23.00M | 4.00M | 5.00M | 6.00M |
| Repurchase of Common Stock | -486.00M | 0.00 | -81.00M | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -3.35B | -3.00M | -1.58B | -17.00M | -3.03B |
| Other Financing Activities | 104.00M | 0.00 | 24.00M | 0.00 | -841.00M |
| Cash from Financing | -2.71B | -671.00M | -4.13B | -1.22B | 2.03B |
| Foreign Exchange rate Adjustments | 25.00M | -61.00M | 20.00M | -6.00M | -46.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -222.00M | 994.00M | -2.24B | -1.02B | 2.06B |